{"id":"ipv-at-14-and-22-weeks-of-age-rotarix","safety":{"commonSideEffects":[{"rate":"10-30","effect":"Injection site reactions (pain, redness, swelling)"},{"rate":"5-15","effect":"Fever"},{"rate":"5-10","effect":"Irritability or fussiness"},{"rate":"5-10","effect":"Diarrhea (Rotarix)"},{"rate":"2-5","effect":"Vomiting (Rotarix)"}]},"_chembl":{"chemblId":"CHEMBL4303347","moleculeType":"Small molecule","molecularWeight":"455.60"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IPV contains chemically inactivated poliovirus particles that trigger humoral and cell-mediated immune responses without causing disease. Rotarix is a live attenuated rotavirus vaccine that replicates in the intestinal tract, inducing mucosal and systemic immunity. Both vaccines work by priming the adaptive immune system to recognize and neutralize the respective pathogens upon natural exposure.","oneSentence":"IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:50:10.120Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of poliomyelitis (IPV component)"},{"name":"Prevention of rotavirus gastroenteritis (Rotarix component)"}]},"trialDetails":[{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IPV at 14 and 22 weeks of age, Rotarix","genericName":"IPV at 14 and 22 weeks of age, Rotarix","companyName":"Centers for Disease Control and Prevention","companyId":"centers-for-disease-control-and-prevention","modality":"Biologic","firstApprovalDate":"","aiSummary":"IPV (inactivated poliovirus vaccine) and Rotarix (rotavirus vaccine) stimulate the immune system to produce antibodies and cellular immunity against poliovirus and rotavirus, respectively, preventing infection and disease. Used for Prevention of poliomyelitis (IPV component), Prevention of rotavirus gastroenteritis (Rotarix component).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}